Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 235

1.

Framing Pragmatic Strategies to Reduce Mortality From Bladder Cancer: An Endorsement From the Society of Urologic Oncology.

de Vere White R, Lara PN Jr, Black PC, Evans CP, Dall'Era M.

J Clin Oncol. 2020 Jan 17:JCO1901731. doi: 10.1200/JCO.19.01731. [Epub ahead of print] No abstract available.

PMID:
31951493
2.

RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype.

Cai D, Wang J, Gao B, Li J, Wu F, Zou JX, Xu J, Jiang Y, Zou H, Huang Z, Borowsky AD, Bold RJ, Lara PN, Li JJ, Chen X, Lam KS, To KF, Kung HJ, Fiehn O, Zhao R, Evans RM, Chen HW.

Nat Commun. 2019 Oct 11;10(1):4621. doi: 10.1038/s41467-019-12529-3.

3.

Immunohistochemical expression of renin is a prognostic factor for recurrence in nonmetastatic renal cell carcinoma.

de Almeida E Paula F, Bezerra SM, da Cunha IW, Munhoz GC, Abreu D, Lara PN Jr, da Costa WH, Zéqui SC.

Urol Oncol. 2019 Dec;37(12):947-954. doi: 10.1016/j.urolonc.2019.07.012. Epub 2019 Aug 28.

PMID:
31473089
4.

First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors.

Piha-Paul SA, Sachdev JC, Barve M, LoRusso P, Szmulewitz R, Patel SP, Lara PN Jr, Chen X, Hu B, Freise KJ, Modi D, Sood A, Hutti JE, Wolff J, O'Neil BH.

Clin Cancer Res. 2019 Nov 1;25(21):6309-6319. doi: 10.1158/1078-0432.CCR-19-0578. Epub 2019 Aug 16.

PMID:
31420359
5.

Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy.

Barzi A, Lara PN Jr, Tsao-Wei D, Yang D, Gill IS, Daneshmand S, Klein EA, Pinski JK, Penson DF, Quinn DI, Sadeghi S.

Cancer. 2019 Nov 1;125(21):3853-3863. doi: 10.1002/cncr.32290. Epub 2019 Aug 9.

PMID:
31398279
6.

Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653).

Sadeghi S, Groshen SG, Tsao-Wei DD, Parikh R, Mortazavi A, Dorff TB, Kefauver C, Hoimes C, Doyle L, Quinn DI, Newman E, Lara PN Jr.

J Clin Oncol. 2019 Oct 10;37(29):2682-2688. doi: 10.1200/JCO.19.00861. Epub 2019 Aug 7.

PMID:
31390274
7.

A Population-Based Study of Incidence and Survival of 1588 Thymic Malignancies: Results From the California Cancer Registry.

Benjamin DJ, Klapheke A, Lara PN, Cress RD, Riess JW.

Clin Lung Cancer. 2019 Nov;20(6):477-483. doi: 10.1016/j.cllc.2019.06.005. Epub 2019 Jun 14.

PMID:
31375453
8.

SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).

Aggarwal C, Redman MW, Lara PN Jr, Borghaei H, Hoffman P, Bradley JD, Newman AJ 3rd, Feldman MJ, Minichiello K, Miao J, Mack PC, Papadimitrakopoulou VA, Herbst RS, Kelly K, Gandara DR.

J Thorac Oncol. 2019 Oct;14(10):1847-1852. doi: 10.1016/j.jtho.2019.05.041. Epub 2019 Jun 11.

PMID:
31195180
9.

Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.

Kim HL, Mayerson E, Lara PN, Messing E, Tangen C, Shuch BM, Vaishampayan U.

Eur Urol Focus. 2019 Nov;5(6):927-929. doi: 10.1016/j.euf.2019.05.006. Epub 2019 May 16.

PMID:
31103605
10.

The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?

Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA, Drake CG, Heng DY, Lara PN, Choueiri TK, Maskens D, Singer EA, Eggener SE, Svatek RS, Stadler WM, Cole S, Signoretti S, Gupta RT, Michaelson MD, McDermott DF, Cella D, Wagner LI, Haas NB, Carducci MA, Harshman LC, Allaf ME.

Future Oncol. 2019 May;15(15):1683-1695. doi: 10.2217/fon-2018-0951. Epub 2019 Apr 10.

PMID:
30968729
11.

Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity.

Aggarwal RR, Quigley DA, Huang J, Zhang L, Beer TM, Rettig MB, Reiter RE, Gleave ME, Thomas GV, Foye A, Playdle D, Lloyd P, Chi KN, Evans CP, Lara PN, Feng FY, Alumkal JJ, Small EJ.

Mol Cancer Res. 2019 Jun;17(6):1235-1240. doi: 10.1158/1541-7786.MCR-18-1101. Epub 2019 Mar 27.

12.

Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303).

Reckamp KL, Frankel PH, Ruel N, Mack PC, Gitlitz BJ, Li T, Koczywas M, Gadgeel SM, Cristea MC, Belani CP, Newman EM, Gandara DR, Lara PN Jr.

Front Oncol. 2019 Mar 11;9:132. doi: 10.3389/fonc.2019.00132. eCollection 2019.

13.
14.

Cytoreductive Nephrectomy in Metastatic Renal Cell Cancer: Not All That It's Cut Out to Be.

Lara PN Jr, Evans CP.

JAMA Oncol. 2019 Feb 1;5(2):171-172. doi: 10.1001/jamaoncol.2018.5503. No abstract available.

PMID:
30543365
15.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Oct 18;175(3):889. doi: 10.1016/j.cell.2018.10.019. No abstract available.

16.

NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma.

Tarhini AA, Frankel P, Ruel C, Ernstoff MS, Kuzel TM, Logan TF, Khushalani NI, Tawbi HA, Margolin KA, Awasthi S, Butterfield LH, McDermott D, Chen A, Lara PN, Kirkwood JM.

Cancer. 2018 Nov 15;124(22):4332-4341. doi: 10.1002/cncr.31734. Epub 2018 Oct 10.

17.

Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study.

Parikh M, Pan CX, Beckett LA, Li Y, Robles DA, Aujla PK, Lara PN Jr.

Clin Genitourin Cancer. 2018 Dec;16(6):421-428.e1. doi: 10.1016/j.clgc.2018.07.004. Epub 2018 Jul 12.

18.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Jul 26;174(3):758-769.e9. doi: 10.1016/j.cell.2018.06.039. Epub 2018 Jul 19. Erratum in: Cell. 2018 Oct 18;175(3):889.

19.

Editorial Comment.

Dall'Era M, Lara PN Jr.

J Urol. 2018 Nov;200(5):1003. doi: 10.1016/j.juro.2018.06.071. Epub 2018 Jul 19. No abstract available.

PMID:
30030973
20.

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC.

Riess JW, Gandara DR, Frampton GM, Madison R, Peled N, Bufill JA, Dy GK, Ou SI, Stephens PJ, McPherson JD, Lara PN Jr, Burich RA, Ross JS, Miller VA, Ali SM, Mack PC, Schrock AB.

J Thorac Oncol. 2018 Oct;13(10):1560-1568. doi: 10.1016/j.jtho.2018.06.019. Epub 2018 Jul 5.

21.

Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421).

Unger JM, Griffin K, Donaldson GW, Baranowski KM, Good MJ, Reburiano E, Hussain M, Monk PJ, Van Veldhuizen PJ, Carducci MA, Higano CS, Lara PN, Tangen CM, Quinn DI, Wade JL III, Vogelzang NJ, Thompson IM Jr, Moinpour CM.

J Patient Rep Outcomes. 2018 Jun 13;2:27. doi: 10.1186/s41687-018-0054-5. eCollection 2017.

22.

In Search of an Oncogene Driver for Squamous Lung Cancer.

Gandara DR, Riess JW, Lara PN Jr.

JAMA Oncol. 2018 Sep 1;4(9):1197-1198. doi: 10.1001/jamaoncol.2018.0774. No abstract available.

PMID:
29902311
23.

Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy.

Ho PY, Duan Z, Batra N, Jilek JL, Tu MJ, Qiu JX, Hu Z, Wun T, Lara PN, DeVere White RW, Chen HW, Yu AM.

J Pharmacol Exp Ther. 2018 Jun;365(3):494-506. doi: 10.1124/jpet.118.247775. Epub 2018 Mar 30.

24.

A contemporary population-based study of testicular sex cord stromal tumours: Presentation, treatment patterns, and predictors of outcome.

Yuh LM, Lara PN Jr, Wagenaar RM, Evans CP, Dall'era MA, Cress R, Yap SA.

Can Urol Assoc J. 2017 Sep;11(9):E344-E349. doi: 10.5489/cuaj.4402.

25.

Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421.

Lara PN Jr, Plets M, Tangen C, Gertz E, Vogelzang NJ, Hussain M, Twardowski PW, Garzotto MG, Monk JP, Carducci M, Goldkorn A, Mack PC, Thompson I, Van Loan M, Quinn DI.

Cancer Treat Res Commun. 2018;16:18-23. doi: 10.1016/j.ctarc.2018.04.005. Epub 2018 Apr 28.

26.

Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry.

Lara JD, Brunson A, Riess JW, Kelly K, Lara PN Jr, Gandara DR.

Lung Cancer. 2017 Oct;112:165-168. doi: 10.1016/j.lungcan.2017.08.015. Epub 2017 Aug 31.

PMID:
29191590
27.

Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type.

Parikh M, Lara PN Jr.

Annu Rev Med. 2018 Jan 29;69:209-221. doi: 10.1146/annurev-med-041916-124132. Epub 2017 Nov 16. Review.

PMID:
29144835
28.

Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer.

Dorff TB, Longmate JA, Pal SK, Stadler WM, Fishman MN, Vaishampayan UN, Rao A, Pinksi JK, Hu JS, Quinn DI, Lara PN Jr.

Cancer. 2017 Dec 1;123(23):4566-4573. doi: 10.1002/cncr.30942. Epub 2017 Aug 22.

29.

Kidney Cancer Incidence in California: End of the Trend?

Morris CR, Lara PN Jr, Parikh-Patel A, Kizer KW.

Kidney Cancer. 2017 Jul 26;1(1):71-81. doi: 10.3233/KCA-170005.

30.

Kidney Cancer: A New Forum for Impactful Scientific Interactions.

Lara PN Jr, Mulders PFA.

Kidney Cancer. 2017 Jul 26;1(1):1. doi: 10.3233/KCA-179001. No abstract available.

31.

Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421.

Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN Jr, Goldkorn A, Garzotto MG, Mack PC, Higano CS, Vogelzang NJ, Thompson IM Jr, Twardowski PW, Van Veldhuizen PJ Jr, Agarwal N, Carducci MA, Monk JP, Quinn DI.

Clin Genitourin Cancer. 2017 Dec;15(6):635-641. doi: 10.1016/j.clgc.2017.05.014. Epub 2017 May 10.

32.

Metabolic reprogramming in clear cell renal cell carcinoma.

Wettersten HI, Aboud OA, Lara PN Jr, Weiss RH.

Nat Rev Nephrol. 2017 Jul;13(7):410-419. doi: 10.1038/nrneph.2017.59. Epub 2017 May 8. Review.

PMID:
28480903
33.

Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models.

Jian C, Tu MJ, Ho PY, Duan Z, Zhang Q, Qiu JX, DeVere White RW, Wun T, Lara PN, Lam KS, Yu AX, Yu AM.

Oncotarget. 2017 May 9;8(19):30742-30755. doi: 10.18632/oncotarget.16372.

34.

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.

Wakelee HA, Gettinger S, Engelman J, Jänne PA, West H, Subramaniam DS, Leach J, Wax M, Yaron Y, Miles DR, Lara PN Jr.

Cancer Chemother Pharmacol. 2017 May;79(5):923-932. doi: 10.1007/s00280-017-3283-z. Epub 2017 Mar 28.

35.

Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer.

Gandara DR, Riess JW, Kelly K, Li T, Mack PC, Lara PN Jr.

Clin Lung Cancer. 2017 Jan;18(1):1-4. doi: 10.1016/j.cllc.2016.12.011. Epub 2016 Dec 24.

PMID:
28082049
36.

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.

Jonasch E, Hasanov E, Corn PG, Moss T, Shaw KR, Stovall S, Marcott V, Gan B, Bird S, Wang X, Do KA, Altamirano PF, Zurita AJ, Doyle LA, Lara PN Jr, Tannir NM.

Ann Oncol. 2017 Apr 1;28(4):804-808. doi: 10.1093/annonc/mdw676.

37.

Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer.

Lara MS, Holland WS, Chinn D, Burich RA, Lara PN Jr, Gandara DR, Kelly K, Mack PC.

Clin Lung Cancer. 2017 May;18(3):281-285. doi: 10.1016/j.cllc.2016.11.006. Epub 2016 Nov 21.

38.

TMPRSS2-ERG fusions unexpectedly identified in men initially diagnosed with nonprostatic malignancies.

Lara PN Jr, Heilmann AM, Elvin JA, Parikh M, de Vere White R, Gandour-Edwards R, Evans CP, Pan CX, Schrock AB, Erlich R, Ross JS, Stephens PJ, McPherson J, Miller VA, Ali SM.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00065. Epub 2017 Nov 2.

39.

Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer.

Li T, Piperdi B, Walsh WV, Kim M, Beckett LA, Gucalp R, Haigentz M Jr, Bathini VG, Wen H, Zhou K, Pasquinelli PB, Gajavelli S, Sreedhara M, Xie X, Lara PN Jr, Gandara DR, Perez-Soler R.

Clin Lung Cancer. 2017 Jan;18(1):60-67. doi: 10.1016/j.cllc.2016.10.003. Epub 2016 Oct 28.

40.

Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.

Cho H, Matsumoto S, Fujita Y, Kuroda A, Menju T, Sonobe M, Kondo N, Torii I, Nakano T, Lara PN, Gandara DR, Date H, Hasegawa S.

J Thorac Oncol. 2017 Mar;12(3):477-490. doi: 10.1016/j.jtho.2016.10.023. Epub 2016 Nov 17. Erratum in: J Thorac Oncol. 2017 May;12 (5):900.

41.

A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study.

Kirschbaum MH, Frankel P, Synold TW, Zain J, Claxton D, Tuscano J, Newman EM, Gandara DR, Lara PN Jr.

Br J Haematol. 2018 Feb;180(3):445-448. doi: 10.1111/bjh.14333. Epub 2016 Sep 21. No abstract available.

42.

Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer.

Riess JW, Lara PN Jr, Gandara DR.

J Clin Oncol. 2016 Nov 1;34(31):3717-3718. doi: 10.1200/JCO.2016.69.0040. No abstract available.

43.

Local Radiation for Extensive Stage Small Cell Lung Cancer: A Step Forward or Running in Place?

Daly ME, Lara PN Jr.

Clin Lung Cancer. 2016 Jul;17(4):237-8. doi: 10.1016/j.cllc.2016.06.001. No abstract available.

PMID:
27346548
44.

Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry.

Yap SA, Yuh LM, Evans CP, Dall'Era MA, Wagenaar RM, Cress R, Lara PN Jr.

World J Urol. 2017 Feb;35(2):277-283. doi: 10.1007/s00345-016-1870-y. Epub 2016 Jun 15.

PMID:
27306686
45.

A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.

Chow H, Ghosh PM, deVere White R, Evans CP, Dall'Era MA, Yap SA, Li Y, Beckett LA, Lara PN Jr, Pan CX.

Cancer. 2016 Jun 15;122(12):1897-904. doi: 10.1002/cncr.29927. Epub 2016 Mar 28.

46.

New and emerging developments in extensive-stage small cell lung cancer therapeutics.

Parikh M, Riess J, Lara PN Jr.

Curr Opin Oncol. 2016 Mar;28(2):97-103. doi: 10.1097/CCO.0000000000000264. Review. Erratum in: Curr Opin Oncol. 2017 Jan;29(1):88.

47.

SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay.

Lara PN Jr, Moon J, Hesketh PJ, Redman MW, Williamson SK, Akerley WL 3rd, Hirsch FR, Mack PC, Gandara DR.

J Thorac Oncol. 2016 Mar;11(3):420-5. doi: 10.1016/j.jtho.2015.11.003. Epub 2015 Dec 25.

48.

Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database.

Lara PN Jr, Moon J, Redman MW, Semrad TJ, Kelly K, Allen J, Gitlitz B, Mack PC, Gandara DR.

Clin Lung Cancer. 2016 Mar;17(2):113-8.e1-2. doi: 10.1016/j.cllc.2015.09.003. Epub 2015 Oct 23.

49.

Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple Kinases.

Quinn DI, Lara PN Jr.

N Engl J Med. 2015 Nov 5;373(19):1872-4. doi: 10.1056/NEJMe1511252. Epub 2015 Sep 25. No abstract available.

PMID:
26406149
50.

Patient-Derived Xenografts for Investigation of Acquired Resistance in Oncogene-Driven Cancers: Building a Better Mousetrap.

Gandara DR, Lara PN Jr, Mack PC.

J Clin Oncol. 2015 Sep 10;33(26):2839-40. doi: 10.1200/JCO.2015.61.9692. Epub 2015 Jul 27. No abstract available.

PMID:
26215942

Supplemental Content

Support Center